Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.06.2017 | case report | Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017

Brentuximab vedotin in a patient with enteropathy-associated T‑cell lymphoma of the small bowel

memo - Magazine of European Medical Oncology > Ausgabe 2/2017
MD Ferdinand Haslbauer


As the prognosis of enteropathy-associated T‑cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody–drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T‑cell lymphoma that affected the jejunum. Standard chemotherapy with CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinued owing to another condition that required surgery, upon which the patient relapsed. However, resumption of brentuximab vedotin therapy restored partial remission within 3 months.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe